IL123383A0 - Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors - Google Patents

Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors

Info

Publication number
IL123383A0
IL123383A0 IL12338396A IL12338396A IL123383A0 IL 123383 A0 IL123383 A0 IL 123383A0 IL 12338396 A IL12338396 A IL 12338396A IL 12338396 A IL12338396 A IL 12338396A IL 123383 A0 IL123383 A0 IL 123383A0
Authority
IL
Israel
Prior art keywords
igf
insulin
treatment
growth factor
binding protein
Prior art date
Application number
IL12338396A
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL123383A0 publication Critical patent/IL123383A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743Insulin-like growth factor binding protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12338396A 1995-09-14 1996-09-12 Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors IL123383A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US373095P 1995-09-14 1995-09-14
PCT/US1996/014623 WO1997009998A2 (en) 1995-09-14 1996-09-12 Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors

Publications (1)

Publication Number Publication Date
IL123383A0 true IL123383A0 (en) 1998-09-24

Family

ID=21707302

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12338396A IL123383A0 (en) 1995-09-14 1996-09-12 Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors

Country Status (8)

Country Link
US (1) US5840673A (en)
EP (1) EP0871475A2 (en)
JP (1) JP2000502322A (en)
AU (1) AU718451B2 (en)
CA (1) CA2232000A1 (en)
IL (1) IL123383A0 (en)
NO (1) NO981127L (en)
WO (1) WO1997009998A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2370003C (en) 1999-01-13 2008-08-19 Tracey Brown A composition and method for the enhancement of the efficacy of drugs
WO2000050067A1 (en) * 1999-02-26 2000-08-31 Saltech I Göteborg Ab Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1
AU2001264769A1 (en) * 2000-05-17 2001-11-26 Oregon Health And Sciences University Induction of apoptosis and cell growth inhibition by protein 4.33
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US20030035788A1 (en) * 2000-09-19 2003-02-20 Desmond Mascarenhas Method for use of IGF-binding protein for selective sensitization of target cells in vivo
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
EP1435986B1 (en) * 2001-09-18 2008-01-02 Bioexpertise, Llc Igf-binding protein-derived peptide
US7166288B2 (en) * 2002-02-13 2007-01-23 The Trustees Of Columbia University In The City Of New York Use of insulin-like growth factor binding protein 3 (IGF-BP3) for inhibition of tumor growth
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
WO2004111262A1 (en) * 2003-06-18 2004-12-23 Pharmacia & Upjohn Company Llc Method of identifying a selective chemotherapeutic agent
WO2005033132A2 (en) * 2003-10-03 2005-04-14 Genentech, Inc. Igf binding proteins
WO2006017824A2 (en) * 2004-08-06 2006-02-16 The Trustees Of Columbia University In The City Of New York Igf-bp3-related methods for inhibiting tumor growth
US7699677B2 (en) * 2004-12-28 2010-04-20 Independent Administrative Institution, Japan Agency For Marine-Earth Science And Technology Profiling float and usage of the profiling float
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
JP5627181B2 (en) * 2005-09-07 2014-11-19 アルケミア オンコロジー ピーティーワイ リミテッド Therapeutic compositions comprising hyaluronan and therapeutic antibodies and methods of treatment
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004030A1 (en) * 1992-08-26 1994-03-03 Celtrix Pharmaceuticals, Inc. Method for systemic treatment of catabolic conditions and systemic tissue injury
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains

Also Published As

Publication number Publication date
AU6975296A (en) 1997-04-01
EP0871475A2 (en) 1998-10-21
NO981127D0 (en) 1998-03-13
MX9801704A (en) 1998-05-31
US5840673A (en) 1998-11-24
CA2232000A1 (en) 1997-03-20
JP2000502322A (en) 2000-02-29
NO981127L (en) 1998-03-13
WO1997009998A3 (en) 1997-04-10
WO1997009998A2 (en) 1997-03-20
AU718451B2 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
IL123383A0 (en) Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors
EP0785276A4 (en) Modification of peptide and protein
HUP9601120A3 (en) Recombinant obese (ob) proteins
GB9225453D0 (en) Binding proteins
AU4230196A (en) Treatment of pancreatic tumors with peptide yy and analogs thereof
ZA969444B (en) Peptides which enhance transport across tissues and methods of identifying and using the same
AU5283793A (en) Recombinant specific binding protein
EP0742793A4 (en) Bcl-2-associated proteins
AU1116297A (en) Flk-1 binding protein
AU3118897A (en) Immunoassay of total insulin-like growth factor binding protein-1
IL106278A0 (en) Bone formation-inducing protein
AU5716696A (en) Decorin binding protein compositions and methods of use
ZA955430B (en) Tumor necrosis factor receptor-ii associated protein kinase and method for their use
EP0750848A4 (en) Modifier and modifier composition for protein-containing substance
AU3120195A (en) Small cell lung carcinoma peptides and binding agents
AU5446694A (en) Process for enhancing the content of a selected amino acid in a seed storage protein
IL114417A0 (en) Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
AU2186895A (en) Polypeptides of lipopolysaccharide binding protein
AU1888692A (en) Composition and method for treating tumors
EP0546081A4 (en) New insulin-like growth factor binding protein (igfbp-4)
ZA963530B (en) Recombinant obese (ob) proteins
HUP9900011A3 (en) Use of protein gax for treating cancer
AU3942097A (en) Amino acid composition and use thereof in treating tumor growth and metastasis
AU4687997A (en) In vivo protein synthesis method
IL128444A0 (en) Conjugated peptides immunological reagent containing same and use thereof for treatment of immunological disorders